Hematologic Oncology | Specialty

Dr. Mehta on the Rationale for Utilizing Parsaclisib in Relapsed or Refractory MCL

February 12th 2021

Amitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.

Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL

February 11th 2021

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Dr. Nath on the Interim Results of the SIERRA Trial in Relapsed/Refractory AML

February 11th 2021

Rajneesh Nath, MD, discusses the interim results of the phase 3 SIERRA trial in patients with relapsed/refractory acute myeloid leukemia.

Orca-T Displays GVHD Prevention, Scalability Potential, and Tolerability in Hematologic Cancers

February 11th 2021

February 11, 2021 - Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.

Iomab-B/Transplant Causes Fewer AEs Versus Conventional Care in AML

February 11th 2021

February 11, 2021 - A conditioning regimen comprised of targeted radiation with Iomab-B led to a lower incidence of sepsis as well as trends toward reduced rates of severe mucositis and febrile neutropenia versus conventional care and standard conditioning regimens in older adults with relapsed or refractory acute myeloid leukemia.

Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML

February 11th 2021

February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

February 11th 2021

Managing MRD-Negative Acute Lymphoblastic Leukemia

February 11th 2021

Omidubicel May Represent New Standard in Hematologic Cancers Eligible for Umbilical Cord Blood Transplantation

February 10th 2021

February 10, 2021 - Hematopoietic recovery following myeloablative transplantation with omidubicel was faster than standard myeloablative umbilical cord blood transplantation and was associated with encouraging clinical benefit.

Dr. Barata on Patient-Reported Toxicities With Axi-Cel at 1-Year of Follow-Up

February 10th 2021

Anna Barata, PhD, discusses patient-reported toxicities with axicabtagene ciloleucel (axi-cel) in patients 1-year post-infusion.

Dr. Wang on the Potential Utility of Ruxolitinib in Pediatric Patients With cGVHD

February 10th 2021

YunZu Michele Wang, MD, discusses the potential utility of ruxolitinib in children and young adult patients with chronic graft-versus-host disease.

Beti-Cel Results in Impressive Activity in Pediatric Transfusion-Dependent Beta-Thalassemia

February 10th 2021

February 10, 2021 - Treatment with the investigative gene cell therapy betibeglogene autotemcel led to durable transfusion independence in 87% of pediatric patients less than 18 years of age with transfusion-dependent beta-thalassemia with a median average hemoglobin of 11.3 g/dL.

CPX-351 Continues to Improve OS in High-Risk AML Subtypes

February 10th 2021

February 10, 2021 - CPX-351 demonstrated improved overall survival at 5 years versus standard 7+3 chemotherapy in older patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Ruxolitinib Delivered at Maximum Dose Peri-Transplant Proves Safe in Myelofibrosis

February 10th 2021

February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.

T-Cell Engagers and Combinations Push Myeloma Paradigm Forward

February 10th 2021

Sikander Ailawadhi, MD, discusses the future of relapsed/refractory multiple myeloma, the potential for retreatment with proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, and the promise of T-cell engagers in the field.

Role of Venetoclax in Chronic Lymphocytic Leukemia

February 10th 2021

Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.

A Look at the ECOG 1912 and iLLUMINATE Trials

February 10th 2021

Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.

Future of MRD Assessment in NDMM

February 10th 2021

ASH Updates on Transplant in NDMM

February 10th 2021

Axi-Cel Active in Relapsed/Refractory B-Cell Lymphomas Irrespective of Chemo Sensitivity

February 9th 2021

February 9, 2021 - Responsiveness to treatment received immediately prior to CAR T-cell therapy may not be associated with post–CAR T outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma who receive axicabtagene ciloleucel.